B2000

B2000 is a novel small molecule inhibitor of the MET tyrosine kinase (hepatocyte growth factor receptor) developed at Brigham University. It is currently in preclinical development for the treatment of acute myeloid leukemia (AML). B2000 targets the HGF/MET signaling pathway, which plays a critical role in the survival of leukemic stem cells (LSCs) and their protection within the bone marrow niche. Beyond its direct cytotoxic effects on AML cells, B2000 acts as an immunomodulator by promoting the polarization of tumor-associated macrophages (TAMs) from an immunosuppressive M2 phenotype to a tumoricidal M1 phenotype. This dual mechanism of action helps overcome niche-mediated resistance and enhances anti-tumor immunity, as demonstrated in various in vitro and in vivo models.